Adlyxin Discontinued: Why Sanofi Pulled the GLP-1 Drug

Adlyxin (lixisenatide), a once-daily injectable GLP-1 receptor agonist for type 2 diabetes, was discontinued from the U.S. market by its manufacturer Sanofi. The drug’s withdrawal was not triggered by a safety crisis but by commercial realities: Adlyxin was outperformed in blood-sugar lowering, lacked the cardiovascular benefits newer competitors could claim, and struggled to gain meaningful market share in an increasingly crowded drug class. For patients who were taking it, the discontinuation raised practical questions about switching to alternatives and what, if anything, was lost when this particular medication left the shelves.

Why Sanofi Pulled Adlyxin

Adlyxin received FDA approval in July 2016, making it one of several GLP-1 receptor agonists available for adults with type 2 diabetes. By the time it launched, the GLP-1 market already included liraglutide (Victoza), exenatide (Byetta and Bydureon), and dulaglutide (Trulicity), with semaglutide (Ozempic) arriving shortly after. The drug entered a field where competitors were not only already established but also dosing less frequently and, in several cases, demonstrating cardiovascular benefits that Adlyxin could not match.

The commercial trajectory was poor almost from the start. A cost-effectiveness analysis comparing once-weekly semaglutide against lixisenatide in patients with inadequate blood-sugar control on basal insulin found that semaglutide dominated, meaning it delivered better outcomes at lower overall cost.¹ Real-world data from other GLP-1 agents told a similar story about patient behavior: dulaglutide users, for example, discontinued treatment at roughly half the rate of patients on once-weekly exenatide.² Once-weekly injections were simply easier for patients to stick with than daily shots, and Adlyxin required daily dosing. The drug also had a difficult path in Europe: in Germany, lixisenatide was removed from the market as early as April 2014, and treatment modification rates among patients who had been prescribed it were exceptionally high, reaching nearly 97% in that country.³

Sanofi ultimately made a business decision that reflected these market signals. The company also marketed Soliqua, a fixed-ratio combination of insulin glargine and lixisenatide, which remained on the market somewhat longer. But standalone Adlyxin simply could not compete for prescriptions against drugs that lowered blood sugar more, came in more convenient dosing schedules, and carried proven heart benefits.

How Adlyxin Differed from Other GLP-1 Drugs

GLP-1 receptor agonists generally fall into two camps: short-acting and long-acting. Adlyxin was unusual in being a short-acting drug that still only required once-daily injection. Its main pharmacological effect targeted the spike in blood sugar that happens after eating, known as postprandial glucose. It accomplished this primarily by slowing down gastric emptying, keeping food in the stomach longer so that sugar entered the bloodstream more gradually.⁴

This gastric-emptying effect was one of Adlyxin’s genuine strengths. Long-acting GLP-1 drugs tend to slow gastric emptying at first, but the body adapts over time, reducing the effect. Lixisenatide did not appear to trigger that same adaptation, meaning its impact on post-meal glucose spikes remained consistent with continued use.⁵ For patients whose main problem was high blood sugar after meals rather than elevated fasting glucose, this profile was a reasonable clinical fit.

The trade-off was that long-acting agents lowered overall blood sugar more aggressively. A systematic review comparing all available GLP-1 receptor agonists found that lixisenatide had the smallest reduction in HbA1c (roughly half a percent versus placebo), while dulaglutide had the largest (about 1.2%). Long-acting agents also reduced fasting glucose significantly more. When researchers compared all the agents head-to-head against each other for weight loss, blood pressure, and hypoglycemia risk, no clinically meaningful differences emerged, but the gap in blood-sugar lowering was clear.⁶ That difference mattered to prescribers, since HbA1c reduction is one of the primary metrics clinicians use when choosing a diabetes drug.

The Cardiovascular Story That Shaped Adlyxin’s Fate

The FDA now requires large cardiovascular outcome trials for new diabetes drugs, and Adlyxin’s trial, called ELIXA, was completed before the drug even reached the U.S. market. ELIXA enrolled over 6,000 patients with type 2 diabetes who had recently experienced a heart attack or been hospitalized for unstable chest pain. Participants received either lixisenatide or placebo on top of their usual care and were followed for a median of about two years.⁷

The results were reassuring but unremarkable. Major cardiovascular events occurred at nearly identical rates in both groups, about 13% in each. Lixisenatide met the statistical bar for noninferiority, meaning it did not raise heart risk, but it showed no cardiovascular benefit whatsoever. Rates of heart-failure hospitalization and death were also similar between the drug and placebo groups.⁸ In strict safety terms, the ELIXA findings were good news: the drug did not cause harm. But the timing was devastating from a competitive standpoint.

Within a few years, large trials of competing GLP-1 receptor agonists demonstrated that liraglutide and semaglutide could actually reduce cardiovascular events and deaths in high-risk patients with type 2 diabetes. These findings transformed prescribing patterns. Clinicians increasingly chose drugs that offered a heart benefit, especially for patients with existing cardiovascular disease. Adlyxin’s neutral cardiovascular profile, once considered adequate, became a liability. Prescribers had no reason to choose a drug that merely did no harm when alternatives actively reduced cardiac events.

What Patients on Adlyxin Were Told to Do

When a diabetes drug gets discontinued, patients do not simply stop treatment. Switching between GLP-1 receptor agonists is common and generally straightforward, though some practical considerations apply.

Clinical guidance suggests that patients who were tolerating the maximum dose of a once-daily GLP-1 agent like lixisenatide (20 micrograms daily) can transition to a once-weekly agent. For dulaglutide or once-weekly exenatide, the recommendation is to start at the full therapeutic dose. For subcutaneous semaglutide, the suggested approach is to begin at the middle dose for about four weeks before stepping up to the full dose, which helps the body adjust and reduces the chance of gastrointestinal side effects.⁹

Most patients who switched found that their new medication controlled blood sugar at least as well, and often better, than Adlyxin had. The one area where the transition might have felt different was post-meal glucose management. Because long-acting GLP-1 agents work primarily on fasting glucose and lose their gastric-emptying effect over time, patients whose glucose spikes were mainly meal-related may have noticed a different pattern of control after switching. In practice, though, the stronger overall glucose lowering of long-acting agents typically more than compensated.

Adlyxin’s Kidney Findings

One of the more interesting pieces of clinical data from lixisenatide came from a kidney-focused analysis of the ELIXA trial. Researchers looked at how the drug affected urinary albumin, a protein that leaks into urine when the kidneys are damaged, a common complication in diabetes.

Among patients who already had significant kidney protein leakage at the start of the trial, lixisenatide reduced urinary albumin levels by about 39% compared to placebo over roughly two years. The drug was also associated with a lower risk of developing new severe protein leakage, even after accounting for differences in blood-sugar control between the groups.¹⁰ For patients with early-stage kidney damage who were not yet losing large amounts of albumin, the effect was much smaller and not statistically significant. And the drug did not appear to slow the overall decline in kidney filtration rate in any subgroup.

These findings were exploratory rather than definitive, since ELIXA was designed to test cardiovascular outcomes, not kidney outcomes. But they added to a broader body of research suggesting that GLP-1 receptor agonists as a class may have protective effects on the kidneys beyond what you’d expect from blood-sugar lowering alone.¹¹ Larger, purpose-built kidney outcome trials for other GLP-1 drugs have since expanded on this signal. Adlyxin’s kidney data is now mostly of academic interest, a footnote in the broader story of the drug class rather than a reason anyone would seek it out.

The Side-Effect Profile Was Not the Problem

One misconception worth clearing up: Adlyxin was not pulled because of safety concerns. The ELIXA trial specifically tracked serious adverse events, severe low blood sugar, pancreatitis, pancreatic tumors, and allergic reactions, and found no significant differences between lixisenatide and placebo on any of those measures.¹² The drug’s day-to-day side effects were the same ones seen across the entire GLP-1 class: nausea, vomiting, and diarrhea, especially during the first weeks of treatment. All GLP-1 receptor agonists carry these gastrointestinal effects, and the systematic review comparing the full class found no clinically meaningful differences between agents on this front.¹³

If anything, Adlyxin had a slightly more favorable tolerability profile than some competitors because its short-acting nature meant drug levels dropped between doses, giving the body a partial rest from the nausea-inducing effects. Some patients who could not tolerate long-acting agents did better on lixisenatide for this reason. But this niche benefit was not enough to sustain a commercially viable product when the efficacy and cardiovascular gaps were so wide.

Lixisenatide’s Unexpected Second Act in Parkinson’s Research

The lixisenatide molecule may have left the diabetes market, but it has found new relevance in an entirely different field. A phase 2 clinical trial published in the New England Journal of Medicine in 2024 tested lixisenatide in people with early Parkinson’s disease. GLP-1 receptor agonists had previously shown neuroprotective effects in animal models of the disease, and this trial was designed to see whether that translated to humans.

The results were striking. After 12 months, participants who received lixisenatide showed essentially no worsening in their motor disability scores, while the placebo group worsened by about 3 points on a standard clinical scale. The difference was statistically significant. Gastrointestinal side effects were common in the treatment group, consistent with what’s known about GLP-1 drugs in general, but the motor benefit was the kind of finding that Parkinson’s researchers rarely see in early-phase trials.¹⁴

The trial was small, and phase 2 results do not always hold up in larger confirmatory studies. A two-month washout period after the treatment phase showed that the motor scores of the lixisenatide group worsened once the drug was stopped, raising questions about whether the benefit was truly neuroprotective or simply symptomatic. Nonetheless, the Parkinson’s finding has generated significant interest in GLP-1 receptor agonists as potential neuroprotective agents, and several larger trials involving both lixisenatide and other drugs in the class are now underway or planned. The molecule that could not compete in the diabetes marketplace may end up having its most lasting scientific impact in neurology.

What the Adlyxin Story Says About Drug Competition

Adlyxin’s arc illustrates something important about how pharmaceutical markets work. A drug does not need to be unsafe or ineffective to fail; it needs to be less effective, less convenient, or less beneficial than its competitors during a period of rapid innovation. When Adlyxin was in development, proving cardiovascular safety was the regulatory bar. By the time it launched, the bar had shifted to cardiovascular benefit. Once-daily injection was considered reasonable when the main alternative was twice-daily exenatide. By 2017, once-weekly options were standard. In a class where seven or eight agents compete for the same patients, the differences between drugs become amplified rather than smoothed over.

The GLP-1 market has only accelerated since Adlyxin’s departure. Semaglutide’s expansion into weight management, tirzepatide’s dual-agonist approach, and the growing evidence for cardiovascular and kidney protection have made this drug class one of the most prescribed in medicine. For patients who were once on Adlyxin, the available alternatives are not merely adequate replacements but, by most measurable endpoints, improvements. The once-daily, postprandial-focused niche that Adlyxin occupied turned out to be too narrow to sustain a product in a field moving this fast.